EASL - The International Liver Congress 2014 49th Annual Meeting of the European Association for the Study of the Liver London, United Kingdom April 9-13 Reported by Jules Levin Presented at the 49th Annual Meeting of the European Association ... National AIDS Treatment Advocacy Project, 5 days ago
Merck's Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection - BusinessWeek, 1 week ago
Efficacy and safety of MK-5172 and MK-8742 ± RIBAVIRIN IN Hepatitis C Genotype 1 Infected Patients with cirrhosis or previous null response: the C-WORTHY Study - National AIDS Treatment Advocacy Project, 1 week ago
3 images for "Mk 5172"
SVR AND SAFETY OF LOWER DOSES OF MK-5172 25 MG AND 50 MG DAILY FOR 12 WEEKS IN HCV GENOTYPE (G)1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS
EASL - The International Liver Congress 2014 49th Annual Meeting of the European Association for the Study of the Liver London, United Kingdom April 9-13 Reported by Jules Levin EASL 2014 April 9-10 London, UK Martin Lagging, Ashley Brown, Ola ...National AIDS Treatment Advocacy Project, 1 week ago Dose-dependent Pharmacokinetics for MK-5172 25 mg, 50 mg, and 100 mg Once Daily for 12 Weeks in HCV Genotype 1 Treatment-nave Non-cirrhotic Patients National AIDS Treatment Advocacy Project, 1 week ago
MK-5172/MK-8742 shows promise in mid-stage trial Positive results have been reported from the ongoing C-WORTHy study, a phase II clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an ...P&T Community, 1 week ago
Current Awards 4/09/2014 DWSP 2014-12 WC0798 Furnish and Deliver One 91) 4-Wheel Drive Loader/Backhoe With Multipurpose Bucket $96,908.25 Island Equipment Inc. dba American Machinery 4/09/2014 14-05A WC0796 Omaopio Tank ...Maui County, 2 days ago
We've seen a little bit of a relief rally over the past couple of days in the overall market with the start of earnings season giving investors hope that the U.S. economy and corporations can keep motoring higher. On the all, though, it's been a ...Motley Fool, 2 days ago
No drug has hit the market running like Gilead Sciences ' ( NASDAQ: GILD ) freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory ...Motley Fool, 2 days ago Merck Hepatitis C combo pill impresses in Phase II Seeking Alpha, 1 week ago Merck Data Show Potent Rival to Gilead's Hepatitis C Pill Bloomberg, 1 week ago Merck Data Show Potent Drug Rival to Gilead's Hepatitis C Pill Washington Post, 1 week ago
Even the wildest Gilead ( NASDAQ: GILD ) bulls seemed to acknowledge that the company was not going to grab and hold 100% share of the hepatitis C (HCV) market. Now the question seems to be shifting to just how much share rivals like AbbVie ( ...Motley Fool, 4 days ago
Merck ( MRK ) presented interim data from an ongoing phase II study on its once-daily, all-oral hepatitis C virus (:HCV) combination regimen MK-5172 (a NS3/4A protease inhibitor) and MK-8742 (a NS5A replication complex inhibitor). The additional ...Yahoo! Finance, 5 days ago Merck Up on Encouraging HCV Data Yahoo! Finance, 1 week ago Merck Up on Encouraging HCV Data - Analyst Blog Benzinga.com, 1 week ago
More from: , Nasdaq...and 2 other sources
LONDON — Response rates to combination therapy with two novel Merck compounds with or without ribavirin were higher than 90% across a cohort of traditionally difficult-to-treat patients with hepatitis C virus, according to new data presented here.Orthopedics Today, 4 days ago
EASL: - (04/14/14) EASL: - (04/14/14) from Jules: Over 10,000 attended this EASL conference organizers reported, in London at the ExCel Center in the Canary Wharf section of London. I have been attending EASL every year since 1998 when the ...National AIDS Treatment Advocacy Project, 4 days ago
on your WebpageAdd Widget >Get your members hooked!